Building the future of AI-powered
care coordination
We're creating a new category: evidence-backed AI assistants for families managing rare genetic conditions.
The opportunity
Americans living with a rare disease
Source: NORD, 2024
Known rare diseases. Most have no specialized care tool.
Source: NIH GARD
Of rare diseases affect children
Source: Global Genes
Why now?
AI has reached a point where it can meaningfully help with medical information synthesis - but only if we build with rigorous constraints and citation infrastructure.
Rare genetic conditions represent a unique opportunity: specialized enough to be tractable, important enough to matter, and underserved enough to create real value.
We're starting with focused work on Phelan-McDermid, Dravet, and Rett, then expanding carefully across rare genetics. We build trust through transparency and restraint.
Competitive advantages
Constrained scope = trust
We only tackle problems where AI can help without hallucination risk. Evidence-first architecture means every claim is traceable.
Specialized beats generic
Rare genetics requires deep domain knowledge. Generic health AI can't handle variant-specific questions or condition nuances.
Community partnerships
We are building toward co-design partnerships with rare-disease foundations and advocacy groups, using trusted networks for product-market fit and distribution.
Moat through rigor
Our hallucination-resistant pipeline and citation infrastructure aren't easy to replicate - they're the product.
Current traction
Building toward partnerships with rare-disease foundations for condition-specific integrations
Private TestFlight beta open with families managing rare conditions, capturing voice notes, photos, vitals, and visit records
Evidence-first pipeline shipped: Sage answers are grounded in family records and include citations, and Sage says so when it can't answer
Public App Store launch on May 21, 2026, beginning with three rare-disease conditions and a roadmap to add more in partnership with patient communities
Get in touch
Interested in partnering with us or learning more about our vision? We'd love to hear from you.